← All trials
NCT03776994
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2018
- Primary completion
- Jun 30, 2020
- Completion date
- Jan 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SRI InternationalLead sponsor
- United States ArmyCollaborator
- SRI InternationalOverall official - principal investigator
Drugs studied
Indications studied
- Infectious Encephalitis
- Brain Diseases
- Central Nervous System Diseases
- Central Nervous System Infections
- Encephalitis
- Encephalomyelitis
- Encephalomyelitis, Equine
- Encephalomyelitis, Venezuelan Equine
- Nervous System Diseases
- RNA Virus Infections
- Togaviridae Infections
- Vaccines
- Virus Diseases
- Alphavirus Infections
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Physiological Effects of Drugs
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.